Clovis Oncology to Highlight Results from Rubraca® (rucaparib) TRITON Prostate Program at ESMO 2018 Congress Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four posters featuring data and highlighting studies from the Rubraca clinical development program w...... 11:00 GMT Wednesday 3rd October 2018
Clovis Oncology Announces Pricing of Public Offerings of Convertible Senior Notes and Common Stock Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the upsizing and pricing of an underwritten public offering of 0 million aggregate principal amount of...... 01:54 GMT Tuesday 17th April 2018
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy...... 12:52 GMT Friday 23rd March 2018
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Hum...... 12:50 GMT Friday 23rd March 2018
Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer Clovis Oncology (NASDAQ: CLVS) announced today that the company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administrat...... 21:05 GMT Monday 9th October 2017
Clovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet Clovis Oncology, Inc. (NASDAQ: CLVS) announced that comprehensive data from the Phase 3 ARIEL3 study of rucaparib for maintenance treatment of advanced ovaria...... 11:00 GMT Wednesday 13th September 2017
Clovis Oncology’s Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial Clovis Oncology, Inc. (NASDAQ: CLVS) today announced topline data from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achieved the pri...... 08:45 GMT Monday 19th June 2017
Trading of Clovis Oncology, Inc. Common Stock Halted Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that NASDAQ has halted trading of the Company’s common stock. The U.S. Food and Drug Administration’s...... 12:04 GMT Tuesday 12th April 2016
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.